Cardiovascular testing firm Prevencio and Quadrant Health said Thursday that they have entered an agreement to integrate Prevencio's HART CVE and HART CADhs blood tests into Quadrant's primary care workflows to better translate the test results into clinical action and measure outcomes.

As indicated by the release of the China Cardiovascular Health and Disease Report 2024, the current number of cardiovascular patients is 330 million and is still on the rise.

Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

Guardant Health Japan said Monday that it has received approval from that country's Ministry of Health, Labour, and Welfare (MHLW) for its Guardant360 CDx as a companion diagnostic for identifying ESR1 mutations in breast cancer patients.

Helio Genomics said Monday that it has partnered to offer its LiverTrace at-home blood test for liver cancer in partnership with liver health telemedicine firm LiverRight.

Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

Presently, the domestic IVD market shows a slow overall growth rate, but with the emergence of new projects, the improvement of industry concentration, and the emergence of assembly line trends, etc., the blood coagulation market will become thriving.

According to basic survey results, the existing main problems for coagulation testing include nonunified standardization, insufficient academic knowledge of blood coagulation, less equipment, few testing items, insufficient sample size, insufficient clinical communication, etc.

Implementation of in Vitro Diagnosis of Thrombosis and Hemostasis in the Chinese Market

With the development of the blood coagulation industry, more and more IVD companies have joined it and actively expanded the related services.